Mesoblast (ASX:MSB) reported Thursday a fiscal first-half loss of $0.042 per diluted share, compared with a loss of $0.0372 a year earlier.

Analysts surveyed by Visible Alpha expected a loss of $0.05.

Revenue for the six months ended Dec. 31, 2024, was $3.2 million, down from $3.4 million a year earlier. Analysts surveyed by Visible Alpha expected $3 million.

The board did not declare a dividend and "do not anticipate paying dividends in the foreseeable future," per the filing.